Stocks · News reference
Nike falls on weak revenue; Synaptics jumps on $123 ON deal; AsiaStrategy surges on tokenization pact; Mangoceuticals drops.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Edwards Lifesciences (NYSE:EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with
U.S. stock futures advanced on Friday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Thursday's higher close.
Mangoceuticals shares fall 12% after hours despite a $2.5 million strategic investment in its antiviral IP subsidiary.
Mangoceuticals announced that its subsidiary MangoRx IP Holdings has secured $2.5 million in strategic investment from two investors for a 25% membership interest. The initial $1.75 million tranche has been received, with the remaining $750,000 due by November 28, 2026. The investment will fund commercialization of the company's antiviral intellectual property portfolio covering oral-surface administered preparations, with potential applications in poultry, livestock, and human oral-care markets valued at approximately $74.6 billion combined.
BTIG analyst Robert Drbul maintains Nike (NYSE:NKE) with a Buy and lowers the price target from $55 to $50.
Synaptics surged 14.5% after amending its $123/share cash buyout by onsemi; AMOD led gainers, while WCT fell 20.3% premarket.